Medical isotope maker Nordion's profit jumps due to gain from unit sale
Sept 5 (Reuters) - Canada's Nordion Inc, a provider of isotopes used in medical imaging, reported a huge jump in third-quarter profit after it recorded an after-tax gain of about $182 million on the sale of its targeted therapies business.
Net profit rose to $180.4 million, or $2.91 per share, from $12.3 million, or 20 cents per share, a year earlier.
Revenue rose 7 percent to $71.7 million.
Nordion completed in July the sale of its targeted therapies division, which includes the liver cancer therapy TheraSphere, to British health care company BTG Plc.
- India trims perks for U.S. staff in dispute over envoy's New York arrest
- Washington, DC city council raises minimum wage to $11.50/hr in 2016
- China confirms near miss with U.S. ship in South China Sea
- Mega Millions lottery winning tickets sold in California, Georgia |
- The Fabulously Entrepreneurial Life of Ronnie Biggs